Abstract
More than 90% of cancer deaths are caused by cancer metastasis. Since cancer metastasis is the main cause of human deaths, so in this article more attention will be paid to it than ever before. Presently, clinical cancer chemotherapies have been targeting on primary tumors rather than on metastatic processes. Since the antimetastatic drugs are different from antiproliferative drugs and underinvestigated, cancer patients’ survival has been improved on a small scale now. To change this stalemate, this problem is reiterated by an analysis of the relationship between pathology, pharmacology and clinical therapy of neoplasm metastasis and it is suggested to improve the outcome of chemotherapy of cancer patients from different possible ways; e.g. to make more efforts to manufacture new types of antimetastatic drugs and optimize use of these drugs in clinics.
Keywords: Cancer chemotherapy, cancer medicinal chemistry, cancer treatment, cancer pathology, cancer pharmacology, neoplasm metastases.
Current Drug Therapy
Title:Cancer Metastasis Treatments
Volume: 8 Issue: 1
Author(s): Da-Yong Lu, Ting-Ren Lu, Hong-Ying Wu and Shan Cao
Affiliation:
Keywords: Cancer chemotherapy, cancer medicinal chemistry, cancer treatment, cancer pathology, cancer pharmacology, neoplasm metastases.
Abstract: More than 90% of cancer deaths are caused by cancer metastasis. Since cancer metastasis is the main cause of human deaths, so in this article more attention will be paid to it than ever before. Presently, clinical cancer chemotherapies have been targeting on primary tumors rather than on metastatic processes. Since the antimetastatic drugs are different from antiproliferative drugs and underinvestigated, cancer patients’ survival has been improved on a small scale now. To change this stalemate, this problem is reiterated by an analysis of the relationship between pathology, pharmacology and clinical therapy of neoplasm metastasis and it is suggested to improve the outcome of chemotherapy of cancer patients from different possible ways; e.g. to make more efforts to manufacture new types of antimetastatic drugs and optimize use of these drugs in clinics.
Export Options
About this article
Cite this article as:
Lu Da-Yong, Lu Ting-Ren, Wu Hong-Ying and Cao Shan, Cancer Metastasis Treatments, Current Drug Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574885511308010003
DOI https://dx.doi.org/10.2174/1574885511308010003 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Breast Cancer Stem Cells (BCSCs) with Liposomal Formulations
Clinical Cancer Drugs Prospective Clinical Applications of CRF Peptide Antagonists
Current Molecular Pharmacology Robotic Assisted Surgery in Gynecology: Current Insights and Future Perspectives
Recent Patents on Biotechnology Different Treatment Strategies for Pediatric Brain Tumors
Current Pediatric Reviews Protein Misfolding in Conformational Disorders: Rescue of Folding Defects and Chemical Chaperoning
Mini-Reviews in Medicinal Chemistry Micro-flow Immunosensor Based on Thin-film Interdigitated Gold Array Microelectrodes for Cancer Biomarker Detection
Current Drug Delivery Pharmacological Targeting of the Inflamed Intestinal Barrier
Current Pharmaceutical Design Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Current Medicinal Chemistry Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Small Non-Coding RNAs as Novel Therapeutics
Current Molecular Medicine Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
Current Drug Targets In Vitro, In Vivo and In Silico Analysis of the Anticancer and Estrogen-like Activity of Guava Leaf Extracts
Current Medicinal Chemistry Design, Synthesis and in vitro Cytotoxicity Evaluation of New 3',4'-bis (3,4,5-trisubstituted)-4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one Derivatives as Promising Anticancer Agents
Letters in Drug Design & Discovery Histone Variants and Composition in the Developing Brain: Should MeCP2 Care?
Current Topics in Medicinal Chemistry Recent Patents in the Field of Radioprotector Development: Opportunities and Challenges
Recent Patents on Biotechnology The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Role of Angiopoietin-like 4 (ANGPTL4), a Member of Matricellular Proteins: from Homeostasis to Inflammation and Cancer Metastasis
Current Angiogenesis (Discontinued) RNA Splicing: Basic Aspects Underlie Antitumor Targeting
Recent Patents on Anti-Cancer Drug Discovery Targeting Strategies for Glucose Metabolic Pathways and T Cells in Colorectal Cancer
Current Cancer Drug Targets